Shire expands rare disease reach

Share this article:

Shire, which is soon to be AbbVie, has finalized a deal with US biotech ArmaGen. The $225-million deal gives Shire worldwide commercialization rights to the experimental enzyme replacement therapy AGT-182, which could be used to treat what the firms describe in a statement as “the central nervous system (CNS) and somatic manifestations in patients with Hunter syndrome.”

Hunter syndrome is a rare disease in which the body can't get rid of cellular waste. Around 1,200 patients have been diagnosed with the genetic disorder.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters